Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endoplasmic reticulum membrane-associated RNA degradation protein (ERMARD) is a transmembrane protein encoded by the ERMARD (C6orf70) gene, localizing to the endoplasmic reticulum and featuring two transmembrane domains near its C-terminus. It is implicated in the process of neuronal migration during brain development, as gene knockout models in rats show impacts on this process. Mutations in ERMARD are associated with periventricular nodular heterotopia type 6 (PVNH6), a developmental malformation of the cortex characterized by misplaced neurons. The protein is not classified as a receptor, enzyme, or transporter, and its precise molecular function remains not well characterized except for an implied role in RNA surveillance or degradation at the endoplasmic reticulum, based on its name and localization. There are no approved drugs or candidate molecules that target ERMARD, and it is not considered a therapeutic target or biomarker in current medical practice.
None reported; mechanisms of action for drugs are not available since ERMARD is not a known therapeutic target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endoplasmic reticulum membrane-associated RNA degradation protein (ERMARD).